Daniel J. Wallace

发表

Antimalarials—the ‘real‘ advance in lupus

D. Wallace, Daniel J. Wallace, 2001, Lupus.

Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study.

I. Bruce, D. Gladman, C. Gordon, 2013, Arthritis and rheumatism.

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus

R. Levy, M. Petri, S. Navarra, 2013, Lupus.

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

D. Isenberg, K. Kalunian, M. Petri, 2015, Annals of the rheumatic diseases.

Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach

I. Bruce, D. Gladman, C. Gordon, 2020, Arthritis care & research.

Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity

D. Gladman, L. Magder, M. Urowitz, 2011, Lupus.

Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics Cohort Using Multistate Modeling

D. Gladman, C. Gordon, D. Isenberg, 2023, Arthritis care & research.

Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort

I. Bruce, D. Gladman, C. Gordon, 2021, Arthritis & rheumatology.

Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study

I. Bruce, D. Gladman, C. Gordon, 2019, Arthritis & rheumatology.

Lupus erythematosus in the 1980s: a survey of 570 patients.

D. Wallace, M. Pistiner, S. Nessim, 1991, Seminars in arthritis and rheumatism.

Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?

D. Wallace, Daniel J. Wallace, 1987, Arthritis and rheumatism.

Prediction of Hospitalizations in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index

I. Bruce, D. Gladman, C. Gordon, 2020, Arthritis care & research.

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

K. Kalunian, M. Petri, R. Furie, 2018, The Lancet.

Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus.

D. Wallace, J. Merrill, J. Condemi, 2012, Arthritis and rheumatism.

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

M. Petri, D. Wallace, J. Merrill, 2009, Arthritis and rheumatism.

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

C. Gordon, K. Kalunian, M. Petri, 2013, Annals of the rheumatic diseases.

Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities

D. Gladman, J. Sánchez-Guerrero, M. Urowitz, 2020, Annals of the Rheumatic Diseases.

Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort

I. Bruce, D. Gladman, M. Urowitz, 2012, Arthritis care & research.

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

J. Merrill, W. Stohl, R. Furie, 2009, Arthritis and rheumatism.

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.

Gerald McGwin, Hong Fang, Caroline Gordon, 2012, Arthritis and rheumatism.

Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials

M. Weisman, E. Rasmussen, J. Ferbas, 2015, Arthritis Research & Therapy.

Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients

I. Bruce, D. Gladman, E. Ginzler, 2017, Arthritis care & research.

Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study

K. Kalunian, M. Petri, W. White, 2013, Arthritis and rheumatism.

Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus

M. Petri, D. Wallace, J. Merrill, 2019, Arthritis & rheumatology.

Anti-C1q antibodies in systemic lupus erythematosus

D. Gladman, A. Orbai, L. Magder, 2015, Lupus.

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

I. Bruce, K. Kalunian, M. Petri, 2018, The Lancet.

Disease-specific patient reported outcome tools for systemic lupus erythematosus.

J. Block, P. Nicassio, M. Weisman, 2012, Seminars in arthritis and rheumatism.

Non-Lymphoma Hematological Malignancies in Systemic Lupus Erythematosus

D. Gladman, O. Nived, M. Urowitz, 2013, Oncology.

Long‐Term Safety of Rituximab in Granulomatosis With Polyangiitis and in Microscopic Polyangiitis

J. Block, P. Merkel, L. Moreland, 2020, Arthritis care & research.

Disease-specific quality of life in patients with lupus nephritis

M. Weisman, D. Wallace, S. Navarra, 2018, Lupus.

Dubois' Lupus Erythematosus

Daniel J. Wallace, Bevra H. Hahn, 1987 .

Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index

I. Bruce, D. Gladman, C. Gordon, 2020, Arthritis & rheumatology.

Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus

D. Gladman, K. Kalunian, O. Nived, 2011, Annals of the rheumatic diseases.